Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study

Abstract

BACKGROUND Glucocorticoids are the cornerstone treatment of polymyalgia rheumatica (PMR) but induce adverse events. OBJECTIVES To evaluate the efficacy and safety of first-line tocilizumab in PMR. METHODS In a prospective open-label study (ClinicalTrials.gov: NCT01713842), 20 glucocorticoid-free patients fulfilling Chuang's PMR criteria, with symptom… (More)
DOI: 10.1136/annrheumdis-2015-208742
View Slides

Topics

Cite this paper

@inproceedings{DevauchellePensec2016EfficacyOF, title={Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study}, author={Val{\'e}rie Devauchelle-Pensec and Jean Marie Berthelot and Divi Y K Cornec and Yves Renaudineau and Thierry Marhadour and sandrine Jousse-Joulin and Sol{\`e}ne Querellou and Florent Garrigues and Michel de Bandt and Maelenn Gouillou and Alain Saraux}, booktitle={Annals of the rheumatic diseases}, year={2016} }